Maternal serum Down syndrome screening was initially introduced as an adjunct to second trimester open neural tube defect screening using alpha fetoprotein (AFP).1,2 Although the initiation of Down syndrome screening represented a significant advance in prenatal care, detection rates were poor. The gene discussed is AFP; the disease is Down syndrome.